To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...